Retrospective analysis evaluates treatment timing effects on outcomes in acute VKH disease, suggesting early corticosteroids are crucial.
Background To evaluate structural and functional outcomes in patients with acute Vogt-Koyanagi-Harada (VKH) disease, based on the timing of systemic corticosteroid (CS) initiation and the early introduction of noncorticosteroid immunomodulatory therapy (IMT). Methods This retrospective single-centre study included 35 consecutive patients (70 eyes) diagnosed with acute Vogt-Koyanagi-Harada disease at a tertiary center in São Paulo, Brazil. Patients received methylprednisolone pulse therapy (1,000 mg/day, 3 days) followed by gradually tapered oral prednisone (1 mg/kg/day). Patients were classified by the timing of CS initiation. The early treatment group (ETG, n = 24) initiated CS within 30 days of onset and comprised two subgroups: CS monotherapy (Group 1, n = 9) and CS plus IMT within 3 months (Group 2, n = 15). Those treated after 30 days because of late presentation formed the late treatment group (LTG, Group 3, n = 11). Follow-up was 24 months with multimodal imaging and full-field electroretinography. Results At 24 months, 98.6% of the eyes achieved BCVA ≤ 0.3 logMAR (Snellen 20/40), with no significant differences among the groups. Compared with Groups 1 and 3, Group 2 achieved a prednisone dose of ≤ 10 mg sooner (7.3 ± 1.8 months; p = 0.043) and had a significantly lower cumulative dose (8,719 ± 3,067 mg; p = 0.02). BCVA worsening episodes occurred less frequently in Group 2 than in Group 3 (6.7% vs. 59.1%; p < 0.001). Compared with the ETG, the LTG presented higher rates of BCVA worsening episodes (59.1% vs. 16.7%; p = 0.004), anterior uveitis recurrences (45.5% vs. 8.3%; p = 0.02), subretinal fibrosis (45.5% vs. 8.3%; p = 0.02), and peripapillary atrophy (72.7% vs. 22.9%; p = 0.003). Adverse events occurred in 7 patients (20%): 6 related to azathioprine and 1 related to CS therapy. Conclusions Early initiation of high-dose CS in VKH disease patients was associated with fewer relapses and structural complications. Early IMT introduction provided a CS-sparing effect, although it did not significantly improve visual or structural outcomes. Prompt CS initiation remains critical; further studies should identify patients who may benefit most from early IMT.
No takes yet. Share an insight, caveat, or question.
Lavezzo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: